Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Time has come for us to blow this greedy lot out of the water. Zimbabwe deserves better than the mismanagement, corruption ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the ...

With markets nosediving over Donald Trump's trade war, the protectionist US president is hearing the first rumblings of ...